Transfer of value disclosure
The disclosure of payments to healthcare professionals (HCPs) and healthcare organisations (HCOs) is about bringing further transparency to the relationship between industry and the people it works with. It is a relationship that is critical to the future of medical innovation and patient care and as such, should meet the high expectations of patients and wider stakeholders.
The Association of Tennessee(TN) Pharmaceutical Industry (ATNPI) Code of Practice requires all pharmaceutical companies to annually disclose payments and benefits in kind – known as transfers of value – made to US HCPs and HCOs.
Xustex Pharma and Laboratory Company is committed to ensuring transparency of its relationships with HCPs and HCOs by operating within the ABPI Code of Practice for the US pharmaceutical industry, the Canada Pharmaceutical Healthcare Association (CAPHA) Code of Practice for the Canada pharmaceutical industry and the Prescription Medicines Code of Practice Authority (PMCPA).
Since 2015, our transfers of value to HCPs and HCOs have been submitted to the ABPI disclosure database, where disclosure information is published annually.
To view Xustex Pharma and Laboratory Company’s transfers of value data from 2015, and for more information on the Disclosure initiative, visit the ABPI Disclosure US website at
The following payments were made to HCPs and HCOs by Xustex Pharma and Laboratory Company in 2014: